Ian E. Krop, MD, PhD, on Managing Toxicities of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer

Posted: Wednesday, February 5, 2020

Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses toxicities associated with trastuzumab deruxtecan, what seems to be most troublesome from patients’ perspective, and tips on how to manage the adverse effects.